A B7-H3-targeted CD28 bispecific antibody enhances the activity of anti-PD1 and CD3 T-cell engager immunotherapies.
Moore GL, Zeng VG, Diaz JE, Bonzon C, Avery KN, Rashid R, Qi J, Nam DH, Jacinto J, Dragovich MA, Kim YK, Balcazar KP, Bakhit CG, Eivazi A, Nguyen H, Muchhal US, Szymkowski DE, Desjarlais JR, Hedvat M.
Moore GL, et al. Among authors: nam dh.
Mol Cancer Ther. 2024 Sep 20. doi: 10.1158/1535-7163.MCT-24-0327. Online ahead of print.
Mol Cancer Ther. 2024.
PMID: 39301613